“Wow big surprise the little group of bashers are so excited to see Patterson test a less effective similar category drug that has more side effects.”

You’re off-target with your comment. Part of Dr. BP’s paper discusses the diagnostics he’s developed to identify longhauler syndrome in patients. Additionally, it will include the symptoms he’s identified for the longhauler symptom scale (endpoints for a trial). These two aspects are important because CYDY will be running a trial soon for longhaulers and we can get an idea of the endpoints that may be part of the trial, although I doubt detailed diagnostics are apart of the CYDY trial.